Market Cap 19.11M
Revenue (ttm) 0.00
Net Income (ttm) -11.13M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 504,000
Avg Vol 162,048
Day's Range N/A - N/A
Shares Out 32.56M
Stochastic %K 20%
Beta 1.58
Analysts Strong Sell
Price Target $8.38

Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatmen...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 9 799 6183
Address:
Building B, 11 HaMenofim Street, Herzliya, Israel
JohnnyBoy272
JohnnyBoy272 Jul. 29 at 3:06 PM
$NRSN I will circle back to this, this seems like such an odd milestone, like someone else put it there? And if the meeting was happening supposedly in Q1 2026, why have the other accelerated shares in 2027 It seems like this piece could be for a partner? I do not know - it seems like a very odd milestone
0 · Reply
JohnnyBoy272
JohnnyBoy272 Jul. 29 at 11:32 AM
$NRSN If anyone is curious they finally updated their corporate deck. They mostly added slides on TDP-43, and more focus on PrimeC biological activity and strong emphasis on efficacy Still nothing on partners which is not a good sign, I am guessing earning report is very soon, likely today or tomorrow. But looks like that partner is nowhere in reach, they really need to sign something otherwise this stock is going to be delisted, they need a clear plan on the delisting notice
0 · Reply
JohnnyBoy272
JohnnyBoy272 Jul. 28 at 9:33 PM
$NRSN I can’t tell if it’s the ATM but those massive spikes of volume seem worrisome Also followed by poor buying, volume is insignificant when this went back to $0.60, was less than a couple thousands of shares Most of the volume came from massive orders being filled at $0.50 to $0.55, it does not look healthy at all Earnings to me is make or break, or this is seriously going to get out of control to the $0.20 if no clear plan is mentioned in financing - they desperately need to mention the partnership should be wrapped by end of August
0 · Reply
Speculator2
Speculator2 Jul. 28 at 5:42 PM
$NRSN Today's volume looks more like investor liquidation than ATM selling. The specific pattern, opening dive to all-time lows followed by a recovery, is consistent with concentrated sell orders from investors. The recovery suggests the stock has found some support at current levels, but that support is thin and dependent on continued buyer interest that has no guaranteed source.
0 · Reply
Cohensha
Cohensha Jul. 28 at 3:56 PM
$NRSN somebody knows if the volume is result of ATM or it’s share holders that dumping shares?
1 · Reply
tiddyy
tiddyy Jul. 28 at 3:46 PM
$NRSN I told you at $0.70, $0.60, $0.50 and next 40 cents Seriously, anyone thinking this stock has any potential, go do some DD, they are currently in their dilution stage, delisting coming up on September 29th, and no catalysts left The only time this tried to get over $1 they pulled the ATM and sold, when will you understand, you guys were the bridge financing 🤣
0 · Reply
tiddyy
tiddyy Jul. 28 at 1:43 PM
$NRSN Delisting soon guys good luck 🚨 Ask yourself this question, they will not leave it till this late, if a partner were in serious talks they would have mentioned the deal is being finalized But no, two months until the stock gets delisted, scraping to survive, Alon has truly used your guys money for the last year to pay off his expenses $35 million market cap in two month, stock needs to almost double with all news out, only thing left is a supposed partner which they have not showed any confidence of getting done anytime soon 😭🫵
0 · Reply
KoalaFlipper
KoalaFlipper Jul. 28 at 12:30 PM
$NRSN wtf how did it jump 12%+ in pre-market and now it says -4.60% something isnt right..
1 · Reply
tiddyy
tiddyy Jul. 28 at 9:39 AM
$NRSN Yes because I exited, and I am glad I did at $0.70, even with a huge loss. I will shit on this company how much I want, no one should buy this by not doing proper DD - No institutional holdings worth nothing (75% owned by retail) - Partnership fell through in March 2026 - Forced Dilution every quarter to pay off operating expenses (35%+ increased shares in 1 year) with multiple warrants - Phase 3 trial delayed for 2 years, and will be delayed until cash is secured - No CMO hired since departure in March 2026 - Company cash balance less than a million - Corporate deck updated last in May, meanwhile website since last year - Poor Investor Relations and communication to shareholders - Massive ATM setup and consistently being used at any spike - nFL biomarker remains unchanged in Phase 2b, meanwhile ALSFRS scores were not significant during placebo vs drug - tdp-43 reduction unproven to slow prog of ALS yet used as a primary talking point You still want to invest?
0 · Reply
tiddyy
tiddyy Jul. 28 at 9:11 AM
$NRSN Someone exited 30,000 shares right now, and no buy orders till $0.51 WOW
1 · Reply
Latest News on NRSN
NeuroSense Therapeutics Slides: Corporate presentation

May 4, 2026, 7:00 AM EDT - 3 months ago

NeuroSense Therapeutics Slides: Corporate presentation


NeuroSense Announces Pricing of Insider-Led PIPE Financing

Apr 28, 2026, 2:30 PM EDT - 3 months ago

NeuroSense Announces Pricing of Insider-Led PIPE Financing


NeuroSense announces departure of Chief Medical Officer

2026-04-26T22:31:45.000Z - 3 months ago

NeuroSense announces departure of Chief Medical Officer


NeuroSense Therapeutics Slides: Corporate presentation

Apr 14, 2026, 7:00 AM EDT - 3 months ago

NeuroSense Therapeutics Slides: Corporate presentation


NeuroSense granted Brazilian patent covering PrimeC composition

2026-04-06T13:34:33.000Z - 4 months ago

NeuroSense granted Brazilian patent covering PrimeC composition


NeuroSense Granted Brazilian Patent Covering PrimeC Composition

Apr 6, 2026, 9:20 AM EDT - 4 months ago

NeuroSense Granted Brazilian Patent Covering PrimeC Composition


NeuroSense Therapeutics Annual report: Q4 2025

Mar 31, 2026, 9:30 AM EDT - 4 months ago

NeuroSense Therapeutics Annual report: Q4 2025


NeuroSense Therapeutics Earnings release: Q4 2025

Mar 31, 2026, 9:30 AM EDT - 4 months ago

NeuroSense Therapeutics Earnings release: Q4 2025


PrimeC New Data to Be Presented at AD/PD™ 2026 Conference

Mar 18, 2026, 8:00 AM EDT - 4 months ago

PrimeC New Data to Be Presented at AD/PD™ 2026 Conference


NeuroSense Therapeutics Slides: Corporate presentation

Mar 11, 2026, 7:00 AM EDT - 5 months ago

NeuroSense Therapeutics Slides: Corporate presentation


NeuroSense initiated with a Buy at Roth Capital

2026-03-10T08:30:39.000Z - 5 months ago

NeuroSense initiated with a Buy at Roth Capital


NeuroSense files $150M mixed securities shelf

2026-01-29T22:30:20.000Z - 6 months ago

NeuroSense files $150M mixed securities shelf


NeuroSense Therapeutics Slides: Corporate presentation

Jan 4, 2026, 7:00 AM EST - 7 months ago

NeuroSense Therapeutics Slides: Corporate presentation


NeuroSense Therapeutics Slides: Corporate Presentation

Dec 9, 2025, 7:00 AM EST - 8 months ago

NeuroSense Therapeutics Slides: Corporate Presentation


NeuroSense Therapeutics Transcript: Status Update

Dec 8, 2025, 8:30 AM EST - 8 months ago

NeuroSense Therapeutics Transcript: Status Update


NeuroSense to Host Investor Webinar on December 8, 2025

Nov 3, 2025, 9:15 AM EST - 9 months ago

NeuroSense to Host Investor Webinar on December 8, 2025


NeuroSense files to sell 333K ordinary shares for holders

2025-10-28T20:36:43.000Z - 9 months ago

NeuroSense files to sell 333K ordinary shares for holders


NeuroSense initiated with an Outperform at Noble Capital

2025-10-14T13:35:14.000Z - 10 months ago

NeuroSense initiated with an Outperform at Noble Capital


NeuroSense Therapeutics Earnings release: Q2 2025

Jul 31, 2025, 6:00 PM EDT - 1 year ago

NeuroSense Therapeutics Earnings release: Q2 2025


NeuroSense initiated with a Buy at D. Boral Capital

2025-05-12T11:30:59.000Z - 1 year ago

NeuroSense initiated with a Buy at D. Boral Capital


NeuroSense Therapeutics Earnings release: Q4 2024

Apr 7, 2025, 4:00 PM EDT - 1 year ago

NeuroSense Therapeutics Earnings release: Q4 2024


NeuroSense Therapeutics Annual report: Q4 2024

Apr 7, 2025, 4:00 PM EDT - 1 year ago

NeuroSense Therapeutics Annual report: Q4 2024


NeuroSense regains Nasdaq compliance

2025-01-06T14:11:26.000Z - 1 year ago

NeuroSense regains Nasdaq compliance


NeuroSense files to sell 5.28M ordinary shares for holders

2024-12-26T21:55:04.000Z - 1 year ago

NeuroSense files to sell 5.28M ordinary shares for holders


NeuroSense Therapeutics Earnings release: Q3 2024

Dec 18, 2024, 8:00 AM EST - 1 year ago

NeuroSense Therapeutics Earnings release: Q3 2024


JohnnyBoy272
JohnnyBoy272 Jul. 29 at 3:06 PM
$NRSN I will circle back to this, this seems like such an odd milestone, like someone else put it there? And if the meeting was happening supposedly in Q1 2026, why have the other accelerated shares in 2027 It seems like this piece could be for a partner? I do not know - it seems like a very odd milestone
0 · Reply
JohnnyBoy272
JohnnyBoy272 Jul. 29 at 11:32 AM
$NRSN If anyone is curious they finally updated their corporate deck. They mostly added slides on TDP-43, and more focus on PrimeC biological activity and strong emphasis on efficacy Still nothing on partners which is not a good sign, I am guessing earning report is very soon, likely today or tomorrow. But looks like that partner is nowhere in reach, they really need to sign something otherwise this stock is going to be delisted, they need a clear plan on the delisting notice
0 · Reply
JohnnyBoy272
JohnnyBoy272 Jul. 28 at 9:33 PM
$NRSN I can’t tell if it’s the ATM but those massive spikes of volume seem worrisome Also followed by poor buying, volume is insignificant when this went back to $0.60, was less than a couple thousands of shares Most of the volume came from massive orders being filled at $0.50 to $0.55, it does not look healthy at all Earnings to me is make or break, or this is seriously going to get out of control to the $0.20 if no clear plan is mentioned in financing - they desperately need to mention the partnership should be wrapped by end of August
0 · Reply
Speculator2
Speculator2 Jul. 28 at 5:42 PM
$NRSN Today's volume looks more like investor liquidation than ATM selling. The specific pattern, opening dive to all-time lows followed by a recovery, is consistent with concentrated sell orders from investors. The recovery suggests the stock has found some support at current levels, but that support is thin and dependent on continued buyer interest that has no guaranteed source.
0 · Reply
Cohensha
Cohensha Jul. 28 at 3:56 PM
$NRSN somebody knows if the volume is result of ATM or it’s share holders that dumping shares?
1 · Reply
tiddyy
tiddyy Jul. 28 at 3:46 PM
$NRSN I told you at $0.70, $0.60, $0.50 and next 40 cents Seriously, anyone thinking this stock has any potential, go do some DD, they are currently in their dilution stage, delisting coming up on September 29th, and no catalysts left The only time this tried to get over $1 they pulled the ATM and sold, when will you understand, you guys were the bridge financing 🤣
0 · Reply
tiddyy
tiddyy Jul. 28 at 1:43 PM
$NRSN Delisting soon guys good luck 🚨 Ask yourself this question, they will not leave it till this late, if a partner were in serious talks they would have mentioned the deal is being finalized But no, two months until the stock gets delisted, scraping to survive, Alon has truly used your guys money for the last year to pay off his expenses $35 million market cap in two month, stock needs to almost double with all news out, only thing left is a supposed partner which they have not showed any confidence of getting done anytime soon 😭🫵
0 · Reply
KoalaFlipper
KoalaFlipper Jul. 28 at 12:30 PM
$NRSN wtf how did it jump 12%+ in pre-market and now it says -4.60% something isnt right..
1 · Reply
tiddyy
tiddyy Jul. 28 at 9:39 AM
$NRSN Yes because I exited, and I am glad I did at $0.70, even with a huge loss. I will shit on this company how much I want, no one should buy this by not doing proper DD - No institutional holdings worth nothing (75% owned by retail) - Partnership fell through in March 2026 - Forced Dilution every quarter to pay off operating expenses (35%+ increased shares in 1 year) with multiple warrants - Phase 3 trial delayed for 2 years, and will be delayed until cash is secured - No CMO hired since departure in March 2026 - Company cash balance less than a million - Corporate deck updated last in May, meanwhile website since last year - Poor Investor Relations and communication to shareholders - Massive ATM setup and consistently being used at any spike - nFL biomarker remains unchanged in Phase 2b, meanwhile ALSFRS scores were not significant during placebo vs drug - tdp-43 reduction unproven to slow prog of ALS yet used as a primary talking point You still want to invest?
0 · Reply
tiddyy
tiddyy Jul. 28 at 9:11 AM
$NRSN Someone exited 30,000 shares right now, and no buy orders till $0.51 WOW
1 · Reply
tiddyy
tiddyy Jul. 28 at 9:07 AM
$NRSN It’s at $0.51 at pre-market, I think delisting notice very soon, 2 months to solve to make this stock go to $35 million market cap
0 · Reply
tiddyy
tiddyy Jul. 27 at 9:44 PM
$NRSN I know shareholders would be happy now at a $1.00 buyout at this point, Alon is pathetic, just sell the company bro, if you really care about ALS sell it off. Stop waiting, you delayed this trial for 2 years, it could have been in the market by now, your team lacks experience as a company This long-term survival metric you keep boasting about of 15 months from phase 2, well guess what buddy, it’s been a lot more than 15 months since this trial was supposed to start. Just seriously sell this off, and move on somewhere else, you clearly do not have the leadership nor capital to execute this, not for the shareholders, but for the actual patients. You did what you can, just move on and sell it off.
0 · Reply
tiddyy
tiddyy Jul. 27 at 1:09 PM
$NRSN If anyone is curious, if they didn’t dilute from 23 million shares to 35 million shares last year, the stock price would be at $0.90 instead of $0.60 Guys broke your previous support which was at $1.00 (post dilution $0.70) It’s starting to become a falling knife, so be wary, they will R/S soon and keep diluting to fill their pockets, they were supposed to start this trial in 2024 btw.
0 · Reply
JohnnyBoy272
JohnnyBoy272 Jul. 27 at 11:04 AM
$NRSN Earnings should be this week, or beginning of next week. I highly hope they mention they have selected a partner and are finalizing details to start the trial by Q4 2026. This will be enough to move the stock. Mention a partner is selected, give a brief skeleton on the details, and say partnership to be finalized by H2 2026. That will be enough, if they are really planning to begin this trial by end of year, from August to October this deal should be finalized
0 · Reply
tiddyy
tiddyy Jul. 27 at 9:08 AM
$NRSN This is so embarrassing, no institution owns more than $47,000 worth of shares of this company 🤣🤣🤣 Out of the 35,000,000 million shares available, institutions own less than 1% This is complete retail, and it’s very telling after the Canada and tdp43 update that no one wants to buy Now if institutions aren’t going to put more than $100,000 down, what makes you think a biotech company will to cover phase 3 costs
0 · Reply
KoalaFlipper
KoalaFlipper Jul. 24 at 7:20 PM
$NRSN just wait they might get some good news from health canada 📈
0 · Reply
Drugtrade
Drugtrade Jul. 24 at 4:09 PM
$NRSN they have no cash and nobody is interested.. typical reverse split dilution
0 · Reply
Babilon1210
Babilon1210 Jul. 24 at 2:33 PM
$NRSN Jesus. Are they trying to scare us out? I feel somen big coming
0 · Reply
KoalaFlipper
KoalaFlipper Jul. 23 at 6:07 PM
$NRSN Phase 2b clinical results for PrimeC in ALS showed a 14.9-month median survival benefit with a hazard ratio of 0.35 (p=0.0037), alongside achievement of the prespecified primary TDP-43 biomarker endpoint (p=0.0421), supporting NeuroSense’s planned New Drug Submission to Health Canada.
0 · Reply
Wizzard88
Wizzard88 Jul. 23 at 5:58 PM
0 · Reply
Speculator2
Speculator2 Jul. 23 at 2:36 PM
$NRSN I did more research on this and reevaluated my thoughts. I now understand that the NDS is indeed the submission vehicle regardless of the review outcome. Health Canada doesn't have two separate submission pathways, a standard NDS pathway and a NOC/c pathway. There is one submission type, the NDS, and the outcome of reviewing that submission can be either: A standard NOC — full approval after complete review An NOC/c — conditional approval with Phase 3 confirmation required A Notice of Deficiency — requesting additional information A refusal to file — if the submission is incomplete This means yesterday's announcement of "proceeding with an NDS" is literally the only way a company proceeds toward any Health Canada approval, whether standard or accelerated. The NDS is not an alternative to NOC/c. It's the prerequisite for it.
0 · Reply
PSM_EmpowerTrading
PSM_EmpowerTrading Jul. 23 at 1:27 PM
🌅📈 Watchlist part 2 ✅ $PLAG .60 support, if above .80, have potential to 1/1.40 ✅ $AEHL .60 support, if above .80, have potential to 1/1.30 ✅ $ZYBT 1.50 support, if above 2, have potential to 2.30/2.60 ✅ Ideal long entry near low current support 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance ⏳⏳ $NRSN $ORKT still in swing accumulation phase 🎯🎯 Goal is GR🤑🤑N, not GR🥵🥵D.
0 · Reply